The effects of lipid-lowering agents (LLA) on reducing systemic and oral inflammation have not been evaluated. Objective To assess the association of LLA use with high-sensitivity C-reactive protein (hs-CRP) and oral inflammation. Design Cross-sectional analysis using baseline data from 1300 overweight/obese participants aged 40-65 years, recruited for the ongoing San Juan Overweight Adults Longitudinal Study. Serum hs-CRP was measured by ELISA, gingival/periodontal inflammation was evaluated as bleeding upon probing (BOP), and LLA was self-reported. Separate logistic models were performed for systemic and oral inflammation. Results In all, 24% participants reported history of dyslipidaemia, of which, 50.3% self-reported LLA use. Sixty percent of the participants had elevated hs-CRP (>3 mg/dl) and 50% had high BOP (defined as at or above the median: 21%). After adjusting for age, gender, smoking, HDL-C, physical activity, diabetes, blood pressure medications, and percent body fat composition, LLA users had significantly lower odds of elevated hs-CRP compared to LLA non-users (OR = 0.58; 95% CI: 0.39-0.85). After adjusting for age, gender, smoking status, educational level, mean plaque index and percent body fat, LLA users had significantly lower odds of high BOP compared to LLA non-users (OR = 0.62; 95% CI: 0.42-0.91). Conclusions Lipid-lowering agents may reduce both systemic and oral inflammatory responses.
|Number of pages||7|
|Journal||Journal of Clinical Periodontology|
|State||Published - Dec 1 2015|
Bibliographical noteFunding Information:
The authors declare that they have no conflict of interest. This work was supported by National Institute of Dental and Craniofacial Research (NIDCR: R01DE020111) and partially supported by National Institute on Minority Health and Health Disparities (NIMHD: 2U54MD007587), and S21 MD001830 Endowment. This work was fully supported by award number R01DE020111 from the National Institute of Dental and Craniofacial Research and partially supported by award 2U54MD007587 from the National Institute on Minority Health and Health Disparities (NIMHD). We also thank Drs. José Vivaldi, Lydia López, Enrique Santiago, Sasha Martínez, and Christine Ritchie for their contributions to SOALS.
© 2015 John Wiley & Sons A/S.
- lipid-lowering agents
- systemic inflammation
ASJC Scopus subject areas